Skip to search formSkip to main contentSkip to account menu

SAR245409

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

XL765

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a major cause of death among breast cancer patients that results from intrinsic and… 
2015
2015
GD 2 ganglioside specific antibody treatment downregulates PI 3 K / Akt / mTOR signaling network in human neuroblastoma cell lines
Mechanisms leading to inhibitory effects of an anti-GD2 ganglioside (GD2) 14G2a mouse monoclonal antibody (mAb) and PI3K/Akt/mTOR… 
2014
2014
443OPIMASERTIB (PIM) AND SAR245409 (SAR) - A MEK AND PI3K/MTOR INHIBITOR COMBINATION: A PHASE IB TRIAL WITH EXPANSIONS IN SELECTED GENOTYPE-DEFINED SOLID TUMORS.
ABSTRACT Aim: To investigate safety and efficacy in four expansion cohorts treated with the combination of PIM and SAR. Methods… 
2014
2014
Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion…
CLL cells are highly dependent on B- cell receptor (BCR) signaling and on stimuli from the microenvironment for survival and… 
2013
2013
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
2530 Background: PI3K/mTOR and MAPK signaling pathways are often deregulated in tumors. Simultaneous inhibition of these pathways… 
2013
2013
Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation…
Background: The PI3K/mTOR and MAPK signaling pathways are frequently aberrated in tumors and interact to promote growth. This… 
2013
2013
SAR245409 Monotherapy in relapsed/refractory follicular lymphoma: preliminary results from the phase II ARD12130 study
Background Dysregulation of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway signaling has been… 
2011
2011
P1-17-09: A Phase 1/2 Dose-Escalation Study of SAR245408 (S08) or SAR245409 (S09) in Combination with Letrozole (L) in Subjects with Hormone Receptor-Positive and HER2−Negative (HR+/HER2−) Breast…
Background: Upregulation of PI3K activity is a common molecular mechanism involved in resistance to AIs. S08 is a potent, orally… 
Highly Cited
2010
Highly Cited
2010
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced…
3030 Background: XL765 is a potent and selective inhibitor of class I PI3K isoforms, TORC1, and TORC2. XL765 has shown dose… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
3015 Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mechanism of resistance… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)